

## Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis

H BIRAN,\* N FRIEDMAN,† L NEUMANN,‡ M PRAS,\*\*  
R SHAINKIN-KESTENBAUM†

From the Departments of \*Oncology, †Nephrology, and ‡Epidemiology, Soroka Medical Center, and Faculty of Health Sciences, Ben-Gurion University, Beer Sheva, and \*\*Heller Institute of Medical Research, Tel-Aviv University, Israel

**SUMMARY** Serum amyloid A (SAA) was determined in 160 patients with cancer. Active disease was associated with high titre compared with the titre in non-active condition (31.8 v 5.8 µg/ml, respectively;  $p = 0.0002$ ). SAA value showed a direct correlation with the stage of the disease: it was lowest at stages 1 and 2 and highest at the metastatic stage 4 (stage 1 v 4,  $p = 0.001$ ; stage 2 v 3,  $p = 0.05$ ). Cancers of the lung and unknown primary site were characterised by highly increased SAA concentration. Initial SAA value had prognostic significance: a value below 10 µg/ml correlated with survival advantage, whereas a higher initial value indicated a greater likelihood of a poor outcome (actuarial survival analysis  $p < 0.001$ ). When stage was accounted for, initial SAA value had significant prognostic bearing on survival of patients with advanced disease (stages 3 and 4) but not on that of patients with limited disease (stages 1 and 2). Serial testing showed good concordance between changes in SAA titre and clinical course.

SAA is an apolipoprotein that is mainly synthesised in the liver. It shows an instantaneous transient rise in response to various stimuli.<sup>1-3</sup> In an extensive report Rosenthal *et al* described the association of active, especially metastatic, malignant diseases with an increase in SAA value.<sup>4</sup> Their basic observation was repeated by other investigators, with some conflicting data regarding the ability of SAA to distinguish between local and metastatic disease.<sup>5,6</sup> Our laboratory recently reported the potential value of SAA assay in the monitoring of prostatic cancer.<sup>7</sup> That study was subsequently extended to additional malignancies.

In this study we defined the extent of disease by an international staging system, followed patient outcome, and analysed the prognostic significance of variations in SAA concentration.

### Material and methods

#### PATIENT POPULATION

The distribution of patients according to diagnosis related in most cases to the primary organ of disease

(Table 1). Evaluation of disease activity was based on physical examination, diagnostic imaging, and, when applicable, tumour markers (such as carcino-embryonic antigen (CEA)). Temporal response to intervention such as surgery, irradiation, or chemotherapy was recorded, as well as recently occurring infection, inflammation, and myocardial infarction. Various staging systems were used in different diseases—such as tumour nodes metastases (TNM) system in breast, Dukes' classification in colorectal, and American Joint Committee staging in lung cancer. Equivalents of the various staging systems were determined following the International Union against Cancer guidelines<sup>8</sup> for analysis.

Fresh serum samples were deep frozen and thawed later for SAA assay. SAA concentrations were determined by radioimmunoassay using purified AA from human amyloidogenic spleen of a familial Mediterranean fever patient and rabbit antibody against human amyloid A. Iodination of amyloid A was performed by the chloramine T method.<sup>9</sup> The assay was carried out as previously described.<sup>10</sup> SAA titres were expressed in µg/ml amyloid A equivalent.

Data processing was aided by the SPSS programs.<sup>11</sup> Actuarial survival was computed by the Kaplan-Meier non-parametric method.<sup>12</sup>

Table 1 Patient characteristics

Diagnosis (primary organ)	No of patients	Sex	
		M	F
Breast	82		82
Colon	20		
Rectum	19	11	8
Colorectal	2		
Stomach	7	7	
Pancreas	3		3
Gall bladder	1	1	
Lung	12	9	3
Sarcoma	5	4	1
Melanoma	3	2	1
Kidney	3	3	
Unknown	10	7	3
Miscellaneous*	4	4	

\*Urinary bladder one; thyroid (medullary) one; anus one; and lymphoma one.

Table 2 SAA and disease activity

Activity	No of patients	Mean (SD) SAA ( $\mu\text{g/ml}$ )
Absent	60	5.8 (7.8)*
Suspected	35	10.1 (7.7)
Present	60	31.8 (52.5)*
Normal control	20	2.0

\* $p < 0.0002$

## Results

### SAA VALUE AND DISEASE ACTIVITY

Table 2 shows SAA value according to clinically evaluated disease activity. The concentration was significantly higher in active than in non-active disease (31.8 v 5.8  $\mu\text{g/ml}$ , respectively;  $p = 0.0002$ ) and was intermediate in suspected cases.

### SAA VALUE AND STAGE OF DISEASE

When patients were stratified according to stage of disease, a direct relation was found between SAA value and stage (Table 3). Titre was low in stages 1 and 2 and increased gradually towards stage 4, where it reached a high value. Differences were significant between stages 2 and 3 and between stages 1 and 4.

Table 3 Relation between stage and SAA value

Stage	No of patients	SAA ( $\mu\text{g/ml}$ )		
		Mean (SD)	Median	Range
1*	37	5.86 (8.64)	4.3	1-11.3
2**	38	5.39 (3.96)	4.1	0.6-
3**	32	24.8 (55.2)	5.7	1.1-264
4*	45	40.6 (55.2)	15.0	1-270

\*1 v 4;  $p = 0.001$

\*\* 2 v 3;  $p = 0.05$ .

### SAA VALUE IN SPECIFIC MALIGNANCIES

Table 4 shows that SAA value varied among the four main malignancies represented by our patient population—namely, breast, colorectal, pulmonary, and cancer of unknown primary site.

Cancer of the lung and cancer with unknown primary site were associated with remarkably high SAA titre compared with that found for mammary and large bowel cancer. As these malignancies were represented more commonly in an advanced stage, however, we had to compare different malignancies at a similar stage. Table 5 analyses patients with advanced disease only. Thus significant differences remained between breast cancer and both cancers of the lung and of unknown primary site.

### INITIAL SAA VALUE AND COURSE OF DISEASE

A cut off initial SAA titre of 10  $\mu\text{g/ml}$  differentiated clearly between patients with favourable and those with unfavourable outcome. Fig. 1 displays actuarial survival of patients based on whether their initial SAA was below or above 10  $\mu\text{g/ml}$ . The median survival of patients who started with the higher titre was slightly over seven months, whereas patients with the lower titre had not yet reached the median at a follow up of 16 months ( $p < 0.001$ ). Further analysis was done to account for stage. Fig. 2 shows that SAA initial titre did not affect survival times of patients grouped together in stages 1 and 2, while it did affect patients grouped together in stages 3 and 4. Median survival of patients in the later stages was short of six months if they started in the higher SAA category, while it had not yet been reached in the other category ( $p < 0.001$ ).

Similarly, at 13 months' median follow up 65 of 106 patients with initial low ( $< 10 \mu\text{g/ml}$ ) SAA stayed free of disease in contrast to only four of 37 with high ( $> 10 \mu\text{g/ml}$ ) titre ( $p = 0.001$ ).

### SERIAL SAA TESTING AND CLINICAL OUTCOME

Forty seven patients had serial SAA determination. In each one the pattern of laboratory changes was confronted with the clinical course. A two fold change in titre was required to define either a decrease or an increase in SAA values. Table 6 shows these results.

Table 4 SAA values in specific malignancies according to primary site

Primary site	No of patients	SAA ( $\mu\text{g/ml}$ )			
		Mean (SD)	Median	Range	Stage 4 (%)
Breast	80	7.76 (10.8)	4.75	0.06-63	16.5
Colorectal	28	15.67 (24.0)	6.4	1.2-99.6	25
Lung	12	62.4 (79.9)	14.9	1.2-264	45.5
Unknown	10	94.5 (84.6)	81.5	2.1-270	80

Table 5 SAA values according to primary site in patients with advanced disease (stages 3 and 4)

Primary site	No of patients	SAA ( $\mu\text{g/ml}$ )		
		Mean (SD)	Median	Range
Breast*	30	12.7 (15.9)	6.0	1-63
Colorectal	11	26.7 (32.4)	10.0	1.6-99.6
Lung*	10	73.5 (83.3)	44.4	1.2-264
Unknown*	10	94.5 (84.6)	81.5	2.1-270

\*Breast v either lung or unknown;  $p < 0.001$ .




Fig. 1 Actuarial survival curve. Patients were divided according to initial SAA values: 1 represents SAA  $\leq 10$  (112 patients); 2 represents SAA  $> 10$  (39 patients); 3 represents all 152 patients.




Fig. 2 Actuarial survival curve. Patients were divided according to initial SAA values and stage: 1 represents SAA  $\leq 10$ , stages 1 and 2 (67 patients); 2 represents SAA  $> 10$ , stages 1 and 2 (seven patients); 3 represents SAA  $\leq 10$ , stages 3 and 4 (44 patients); 4 represents SAA  $> 10$ , stages 3 and 4 (32 patients).

Table 6 Clinical course v SAA values in serial testing

Clinical course	SAA values			Total no of patients
	No change	Decrease > two fold	Increase > two fold	
No change	23*	3	3	29
Remission		5*		5
Progression	3		10*	13
Total	26	8	13	47

\*represents concordance.

Changes in SAA were in accordance with the clinical course in 38 of 47 (80.8%) cases.

## Discussion

Several investigators collaborating with different laboratories studied SAA in malignancy and reported on its common increase in metastatic disease. Authors are not unanimous about the ability of SAA to distinguish between local and metastatic cancer, though reports favouring such an ability<sup>4,6</sup> outnumber the discordant one.<sup>5</sup> Conceivably, this controversy stems from the study of patient populations that are heterogeneous with regard to specific malignancy, stage, and distribution of metastatic sites. Furthermore, non-uniform staging does not permit us to compare different studies with regard to either "local" or "metastatic" disease, unless clear definitions are given.

The results of this study indicated that there is a concomitant rise in SAA value the more advanced the stage. Significant increase was found not only from stage 1 (early local disease) to stage 4 (metastatic disease) but also from stage 2 to stage 3, which is still non-metastatic, though usually incurable. Certain tumours—that is, cancers of the lung and of unknown primary site seem to produce a particularly high SAA titre that cannot be accounted for by advanced stage alone. The observation regarding lung cancer has been mentioned, though not emphasised, previously. For instance, Rosenthal found an appreciable increase in small cell bronchogenic cancer, even in limited disease.<sup>4</sup>

An important objective of the study was to explore the prognostic value of SAA assay. As actuarial survival shows, lower initial titre correlated with significant survival advantage, in contrast to higher titre, which had unfavourable prognostic bearing on patients. In addition, serial assessment disclosed good concordance of laboratory and clinical ranges. Remission after treatment was paralleled by a decrease in SAA, while progression was accompanied, in most cases, by an increase.

Although SAA is not a tumour specific marker and does not fulfil the criteria for an "ideal marker,"<sup>13</sup> we feel that it has potential value in the initial assessment

of patients with cancer who have active disease, as well as in the monitoring of therapeutic results. It could be helpful when other available markers such as CEA are negative; it may also be added to a panel of other markers to increase their diagnostic power.

The assay may be selectively applied in diseases such as lung cancer, in which high titres facilitate interpretation of results.

## References

- Benditt EP, Erikson N. Amyloid protein SAA is associated with high density lipoprotein from human serum. *Proc Natl Acad Sci USA* 1977;74:4025–28.
- Levin M, Pras M, Franklin EC. Immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of related serum component. *J Exp Med* 1973;138:373–80.
- Rosenthal CJ, Franklin EC. Variation with age and disease of an amyloid A protein-related serum component. *J Clin Invest* 1975;55:746–53.
- Rosenthal CJ, Sullivan LM. Serum amyloid A to monitor cancer dissemination. *Ann Intern Med* 1979;91:383–90.
- Raynes JG, Cooper EH. Comparison of serum amyloid A protein and C-reactive protein concentration in cancer and non-malignant disease. *J Clin Pathol* 1983;36:798–803.
- Weinstein PS, Skinner M, Sipe JD, Lokich J, Zamcheck N, Cohen SA. Acute phase proteins or tumour markers. *Scand J Immunol* 1984;19:193–8.
- Kaneti J, Winikoff Y, Zimlichman S, Shaikin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. *Urol Res* 1984;12:239–41.
- UICC—International Union Against Cancer. *TNM—classification of malignant tumours*. 3rd ed. Geneva: 1978.
- Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. *Nature* 1963;194:945.
- Shaikin-Kestenbaum R, Zimlichman S, Winikoff Y, Pras M, Chaimovitz C, Sarov I. Serum amyloid A in viral infection. *Clin Exp Immunol* 1982;50:503.
- Nie NH, Hadlai Hull C, Jenkins G. *SPSS—statistical package for the social sciences*. 2nd ed. New York: McGraw-Hill, 1975.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *Journal of the American Statistical Association* 1958;53:457–81.
- Klee GG, Go VLW. Serum tumour markers. *Mayo Clin Proc* 1982;57:129.

Requests for reprints to: Dr H Biran, Department of Oncology, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84101, Israel.